No Data
No Data
Shareholder of Guangyuyuan (600771.SH) plans to increase shareholding by 50 million yuan to 0.1 billion yuan.
Guangyuyuan (600771.SH) announced on August 26, 2024 that its controlling shareholder, Hainan Shennong Technology Group,...
Guangyuyuan Chinese Herbal Medicine Co., Ltd. 2024 Interim Report.
Summary of Guangyuyuan Chinese Herbal Medicine Co., Ltd.'s 2024 semi-annual report
Guangyuyuan (600771.SH): The net income in the first half of the year was 59.6031 million yuan, a year-on-year increase of 13.75%.
On August 22, Guangyuyuan (600771.SH) released its semi-annual report, achieving a revenue of 0.66 billion yuan during the reporting period, a decrease of 4.90% year-on-year; the net income attributable to the listed shareholders was 59.6031 million yuan, a year-on-year increase of 13.75%. The high-quality traditional Chinese medicine has received support from policy upgrades, and efforts have been made to strengthen the empowerment of the terminal, as well as continuous investment in brand building. The company participated in 4 national-level conferences, 46 high-level circle events, and hosted over 20 activities in various terminal stores. During the reporting period, the company initiated control policy execution for the first time, while integrating the existing national medical institutions, national pharmacies, and museums.
GuangYuYuan Chinese Herbal Medicine Co., Ltd.'s (SHSE:600771) Popularity With Investors Is Under Threat From Overpricing
Guangyuyuan Chinese Herbal Medicine (600771.SH): The product, Dingkun Dan, has been included in the national medical insurance pharmaceutical directory, while Guilin Jie has not been included yet.
Guangyuyuan (600771.SH) stated on the investor interaction platform on August 16th that currently the company's Dingkun Dan product has been included in the National Medical Insurance Pharmaceutical Catalog, while Gui Ling Ji is not yet included.
No Data
No Data